Treatment of recalcitrant orbital inflammatory syndrome with plasmapheresis therapy.


Journal

BMJ case reports
ISSN: 1757-790X
Titre abrégé: BMJ Case Rep
Pays: England
ID NLM: 101526291

Informations de publication

Date de publication:
08 Jan 2020
Historique:
entrez: 11 1 2020
pubmed: 11 1 2020
medline: 20 8 2020
Statut: epublish

Résumé

Refractory idiopathic orbital inflammation (IOI) represents a management challenge due to its significant proportion of treatment failures. Currently, there are no established guidelines for recalcitrant IOI and majority of immunosuppressive agents have resulted in variable outcomes. Advancements of plasmapheresis therapy can play a significant role in ophthalmological diseases. This treatment has shown to produce a satisfactory therapeutic response in immune-mediated neurological conditions. In this case report, we share our successful experience with the use of plasmapheresis therapy in a patient with recalcitrant IOI.

Identifiants

pubmed: 31919064
pii: 13/1/e232379
doi: 10.1136/bcr-2019-232379
pmc: PMC6954793
pii:
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0
Rituximab 4F4X42SYQ6

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Ophthalmic Plast Reconstr Surg. 2006 Mar-Apr;22(2):79-86
pubmed: 16550048
Eye (Lond). 2006 Oct;20(10):1196-206
pubmed: 17019419
Clin Rheumatol. 2009 Feb;28(2):225-6
pubmed: 19015801
Int Ophthalmol. 2018 Aug;38(4):1485-1495
pubmed: 28634929
Neurology. 2011 Jun 7;76(23):2017-23
pubmed: 21562253
Am J Ophthalmol. 2005 Nov;140(5):916-8
pubmed: 16310473
Am J Ophthalmol. 2004 Dec;138(6):1041-3
pubmed: 15629299
Muscle Nerve. 2013 Apr;47(4):510-4
pubmed: 23322564
Neurologist. 2007 Jan;13(1):2-11
pubmed: 17215722
Arch Ophthalmol. 2003 Apr;121(4):491-9
pubmed: 12695246
Ocul Immunol Inflamm. 2015 Apr;23(2):176-9
pubmed: 24354478
Am J Ophthalmol. 2004 Dec;138(6):925-30
pubmed: 15629282
Curr Rheumatol Rep. 2010 Dec;12(6):443-7
pubmed: 20803107
J Clin Apher. 2011 Dec;26(6):356-61
pubmed: 21898575

Auteurs

Yasaira Rodriguez Torres (Y)

Ophthalmology, Kresge Eye Institute, Detroit, Michigan, USA yrodrigu@med.wayne.edu.

Fereshteh Azad (F)

Ophthalmology, Kresge Eye Institute, Detroit, Michigan, USA.

Xihui Lin (X)

Ophthalmology, Kresge Eye Institute, Detroit, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH